Torna al Registre Simple

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorCelada, Lucía
dc.contributor.authorRUIZ-CANTADOR, JOSE
dc.contributor.authorda Silva Alves Pereira, Bianca Gabriela
dc.contributor.authorIglesias Felip, Carmela
dc.contributor.authorCasteràs, Anna
dc.contributor.authorArenillas, Carlota
dc.contributor.authorCalsina, Bruna
dc.contributor.authorDatta, Debayan
dc.contributor.authorGarcía-Galea, Eduardo
dc.contributor.authorfasani, roberta
dc.contributor.authorMoreno-Cárdenas, Ana Belén
dc.contributor.authorMiranda, Berta
dc.contributor.authorDienstmann, Rodrigo
dc.contributor.authorVillanueva Cardús, Josep
dc.contributor.authorCapdevila Castillon, Jaume
dc.contributor.authorNuciforo, Paolo
dc.contributor.authorDOS SUBIRA, LAURA
dc.contributor.authorToledo, Rodrigo
dc.date.accessioned2025-05-20T10:45:40Z
dc.date.available2025-05-20T10:45:40Z
dc.date.issued2025-05-01
dc.identifier.citationArenillas C, Celada L, Ruiz-Cantador J, Calsina B, Datta D, García-Galea E, et al. Convergent Genetic Adaptation in Human Tumors Developed Under Systemic Hypoxia and in Populations Living at High Altitudes. Cancer Discov. 2025 May 1;15(5):1037-62.
dc.identifier.issn2159-8290
dc.identifier.urihttp://hdl.handle.net/11351/13110
dc.descriptionGenètica; Tumors humans; Hipòxia sistèmica
dc.description.sponsorshipThe authors would like to thank especially patients and their families for their participation and contribution to this research study. We acknowledge IdiPAZ Biobank for the assistance in some tumor samples collection; VHIO’s Oncology Data Science (ODysSey) for carrying out some statistical analyses; European Network for the Study of Adrenal Tumors (ENS@T) and COST Action CA20122 Harmonisation for supportive networking; FERO Foundation for providing a startup grant for VHIO’s Biomarkers and Clonal Dynamics Laboratory led by R.A. Toledo; and Editage for its editing services. VHIO would like to acknowledge: the State Agency for Research (Agencia Estatal de Investigación) for the financial support as a Center of Excellence Severo Ochoa (CEX2020-001024-S/AEI/10.13039/501100011033), the Cellex Foundation for providing research facilities and equipment, the CERCA Programme from the Generalitat de Catalunya for their support on this research, and the Banco Bilbao Vizcaya Argentaria (BBVA) Foundation for supporting the Comprehensive Program of Cancer Immunotherapy and Immunology (CAIMI-I and CAIMI-II, grant no. 53/2021). In memory of Dr. José María Oliver, who played a pivotal role in the development of the field of Adult Congenital Heart Diseases in Spain and his early assessment of CCHD and PPGL association. The sponsors of this study listed below supported the costs related to the research experiments and salary of the investigators. Paradifference Foundation supported this PPGL research and provided funding support to J. Favier, M. Robledo, I. Adameyko, P.L.M. Dahia, and R.A. Toledo. The Pheipas Patient Association provided a research grant to R.A. Toledo for the study of PPGL tumors (grant #914300). C. Arenillas was supported by a CIBERONC predoctoral fellowship. R.A. Toledo holds a Miguel Servet-I research contract and a Plan Nacional grant by the Institute of Health Carlos III (ISCIII) of the Ministry of Economy and Competitiveness from the Spanish government (grants #CP17/00199 and #PID2021-126297OA-I00). P.L.M. Dahia received grants from the NIH/NIGMS (#GM114102), NIH/NCI (#CA264248), Neuroendocrine Tumor Research Foundation (NETRF), VHL Alliance, Paradifference Foundation and is the holder of the Robert Tucker Hayes Distinguished Chair in Oncology. M.-D. Chiara received grants from the Institute of Health Carlos III (ISCIII) of the Ministry of Economy and Competitiveness from the Spanish government (grants #PI20/01754 and #PID2023-151388OB-I00). J. Capdevila was partially supported by the Institute of Health Carlos III (ISCIII; #PI20/00895) and co-funded by the European Union (ERDF/ESF)—A way to build Europe and the Enric Masip Foundation. C. Arenillas, B. Calsina, T. Cubiella, J. Favier, M. Robledo, M.-D. Chiara, and R.A. Toledo were awarded with travel grants by European Cooperation in Science and Technology (COST) Action CA20122 Harmonisation.
dc.language.isoeng
dc.publisherAmerican Association for Cancer Research
dc.relation.ispartofseriesCancer Discovery;15(5)
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourceScientia
dc.subjectCàncer - Aspectes genètics
dc.subjectAdaptació (Fisiologia)
dc.subjectAnoxèmia
dc.subjectAltituds
dc.subject.meshNeoplasms
dc.subject.mesh/genetics
dc.subject.meshHypoxia
dc.subject.meshAltitude
dc.subject.meshAdaptation, Physiological
dc.subject.mesh/genetics
dc.titleConvergent Genetic Adaptation in Human Tumors Developed Under Systemic Hypoxia and in Populations Living at High Altitudes
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1158/2159-8290.CD-24-0943
dc.subject.decsneoplasias
dc.subject.decs/genética
dc.subject.decshipoxia
dc.subject.decsaltitud
dc.subject.decsadaptación fisiológica
dc.subject.decs/genética
dc.relation.publishversionhttps://doi.org/10.1158/2159-8290.CD-24-0943
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Arenillas C] Biomarkers and Clonal Dynamics Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Salud Carlos III (ISCIII), Madrid, Spain. Department of Medicine, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Celada L] Health Research Institute of Asturias (ISPA), University of Oviedo, Oviedo, Spain. Institute of Oncology of Asturias (IUOPA), University of Oviedo, Oviedo, Spain. [Ruiz-Cantador J] Adult Congenital Heart Disease Unit, Department of Cardiology, Hospital Universitario La Paz, Madrid, Spain. [Calsina B] Hereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain. [Datta D, Moreno-Cárdenas AB] Biomarkers and Clonal Dynamics Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [García-Galea E] Oncology Data Science (ODysSey) Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Fasani R, Nuciforo P] Molecular Oncology Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Miranda-Barrio B] Department of Medicine, Universitat Autònoma de Barcelona, Bellaterra, Spain. Unitat Integrada de Cardiopaties Congènites de l’Adolescent i l’Adult, Servei de Cardiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III (ISCIII), Madrid, Spain. European Reference Network for Rare, Low-Prevalence, or Complex Diseases of the Heart (ERN GUARD-Heart), Amsterdam, the Netherlands. [Robles-Guirado JÁ, Villanueva J] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Iglesias C] Servei d’Anatomia Patològica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona (UAB), Bellaterra, Spain. [Dienstmann R] Oncology Data Science (ODysSey) Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. University of Vic – Central University of Catalonia, Vic, Spain. [Capdevila J] Neuroendocrine and Endocrine Tumor Translational Research Program, Vall Hebron Institute of Oncology (VHIO), Barcelona, Spain. Servei d’Oncologia Mèdica, Grup de Tumors Gastrointestinals i Endocrins, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Casteràs A] Department of Medicine, Universitat Autònoma de Barcelona, Bellaterra, Spain. Servei d’Endocrinologia i Nutrició, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Dos-Subirà L] Unitat Integrada de Cardiopaties Congènites de l’Adolescent i l’Adult, Servei de Cardiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III (ISCIII), Madrid, Spain. European Reference Network for Rare, Low-Prevalence, or Complex Diseases of the Heart (ERN GUARD-Heart), Amsterdam, the Netherlands. [Toledo RA] Biomarkers and Clonal Dynamics Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
dc.identifier.pmid40199338
dc.identifier.wos001480529400014
dc.relation.projectidinfo:eu-repo/grantAgreement/ES/PE2017-2020/PID2021-126297OA-I00
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Fitxers en aquest element

Portada del document

Aquest element apareix en la col·lecció o col·leccions següent(s)

Torna al Registre Simple